SNUG01

Phase 2Small molecule

SSineuGene Therapeutics Co., Ltd.

SNUG01 is one of 56 small molecule programs targeting Amyotrophic Lateral Sclerosis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Amyotrophic Lateral SclerosisNot yet recruiting

Adult SubjectNot yet recruiting

Amyotrophic Lateral SclerosisPhase 1

Not yet recruiting

Adult SubjectPhase 2

Not yet recruiting

Competition

Competitive Landscape

55 competitors in Amyotrophic Lateral Sclerosis

#DrugCompanyPhaseTrials

Enablex

Vimpat

Nourianz

Kyowa Kirin Co., Ltd.

Approved

—4

Bosulif

PPrism Pharmaceuticals

Approved

1 5

Qalsody

Biogen

Approved

3 6

Rocephin

CConrado Roberto Hoffmann Filho

Approved

—7

Rapamune

PPrism Pharmaceuticals

Avodart

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Approved

—10

Atropen

FFresenius Kabi Taiwan Ltd.

Approved

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

Phase 1/2Not yet recruiting

Adult Subject

NCT07169175

Q4 2029

Phase 1Not yet recruiting

Amyotrophic Lateral Sclerosis

NCT06645197

Clinical

Trials by Indication[1]

Adult Subject1 trial

A Phase Ⅰ/Ⅱa Study of SNUG01 in Adult Subjects With ALS

Not yet recruiting·SSineuGene Therapeutics Co., Ltd.·Phase 1/2·NCT07169175·21 enrolled

Amyotrophic Lateral Sclerosis1 trial

An IIT Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of a Single Intrathecal Injection of SNUG01 in Patients with Amyotrophic Lateral Sclerosis

Not yet recruiting·PPeking University Third Hospital·Phase 1·NCT06645197·7 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for SNUG01. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — SNUG01 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for SNUG01. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — SineuGene Therapeutics Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: SSineuGene Therapeutics Co., Ltd.

SNUG01

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2028

Q4 2029

Trials by Indication[1]

Adult Subject1 trial

Amyotrophic Lateral Sclerosis1 trial

References

Drug Info

Quick Facts

Related News